Prelude Therapeutics Net Worth
Prelude Therapeutics Net Worth Breakdown | PRLD |
Prelude Therapeutics Net Worth Analysis
Prelude Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Prelude Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Prelude Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Prelude Therapeutics' net worth analysis. One common approach is to calculate Prelude Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Prelude Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Prelude Therapeutics' net worth. This approach calculates the present value of Prelude Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Prelude Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Prelude Therapeutics' net worth. This involves comparing Prelude Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Prelude Therapeutics' net worth relative to its peers.
To determine if Prelude Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Prelude Therapeutics' net worth research are outlined below:
| Prelude Therapeutics generated a negative expected return over the last 90 days | |
| Prelude Therapeutics has high historical volatility and very poor performance | |
| Prelude Therapeutics has some characteristics of a very speculative penny stock | |
| Prelude Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7 M. Net Loss for the year was (127.17 M) with profit before overhead, payroll, taxes, and interest of 7 M. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (102.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 69.0% of the company shares are owned by institutional investors |
Prelude Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Prelude Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Prelude Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Prelude Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 40.66 M.Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prelude Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prelude Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prelude Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Prelude Therapeutics time-series forecasting models is one of many Prelude Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Prelude Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Prelude Therapeutics Earnings per Share Projection vs Actual
Prelude Therapeutics Corporate Management
| WanJen MD | Senior Development | Profile | |
| Laurent MBA | Chief Officer | Profile | |
| William MD | Senior Development | Profile | |
| Naveen Babbar | Senior Medicine | Profile | |
| Neelesh MD | VP Devel | Profile | |
| Aimee Crombie | Senior Operations | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.